Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Orexigen has released their 2016 fourth quarter results. The revenues are surprisingly soaring high, but the stocks are currently not doing as well as expected in the market. VIVUS on the other hand seeks to reacquire commercialization rights for its erectile dysfunction drug from Sanofi. The acquisition involves its markets in Africa, Turkey, the Middle-East and Commonwealth of Independent States, including Russia. VIVUS has lost 3.5% of its stock value this year, and the reacquisition of its rights has been termed as strategic to cushion further reductions in the stock price.

RDI Initiates
Coverage:

Orexigen
Therapeutics, Inc. https://ub.rdinvesting.com/news/?ticker=OREX

VIVUS, Inc. https://ub.rdinvesting.com/news/?ticker=VVUS

The pharmaceutical company’s stocks dipped 5.90% by the end of business yesterday, to trade at $3.99. The company is currently struggling to break even, with the value of stocks plummeting to $1.67 a share in December 2016 from $6.4 in June 2016. Quarterly profits however remained high, as the company registered $13.9 in revenue at the end of 2016.

While releasing the quarterly results, CEO Mike Narachi cited an increase in sales, even though the stock price is on a free fall. The company has announced that in 2017 it expects a cash balance of between $40 million and $50 million. The company also expects operating expenses to range from $115 million to $125 million. With regard to Zacks rank, Orexigen is at number 3 (hold), with Heska Corporation and Addus HomeCare Corp being the highest ranked stocks.

Access RDI’s Orexigen Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=OREX

VIVUS’ shares recovered from a significant dip yesterday, to close yesterday at $1.11, a 1.85% increase from Tuesday’s closing value. According to Zacks Equity Research, the company recently announced the completion of an agreement to retrieve the commercial rights of its erectile dysfunction drug Stendra from Sanofi SNY.

VIVUS will acquire commercialization rights involving the African market, Middle East, Turkey and Commonwealth of independent states including Russia. Sanofi is expected to ease out the transition process, with regard to regulatory requirements especially in the Russian and Middle East markets. The reacquisition proved imminent with investors saying the move couldn’t have come at a better time.

Access RDI’s VIVUS Research Report at: https://ub.rdinvesting.com/news/?ticker=VVUS

Our Actionable Research on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and VIVUS, Inc. (NASDAQ: VVUS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458546